DIFFUSION TENSOR IMAGING IN FIRST EPISODE SCHIZOPHRENIA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 很少有描述针对了解精神分裂症患者在接受抗精神病药物治疗之前脑白质微结构异常的作用，以及这些药物对脑白质完整性测量的潜在影响。在这项初步研究中，我们计划使用扩散张量成像(DTI)技术，调查在治疗开始时首次发作精神分裂症，然后经过12周标准化治疗的患者的脑白质异常。假设患者将在基线时表现出额叶和颞叶的白质异常，并且在抗精神病药物治疗后，这些区域的白质完整性将会增加。这些数据将被用来证明收集纵向DTI数据的可行性，以便将来向NIMH提交赠款。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Little description has been directed at understanding the role of white matter microstructural abnormalities in schizophrenia prior to treatment with antipsychotic agents and the potential effects of these medications on measures of white matter integrity. In this pilot study, we plan to investigate white matter abnormalities, using diffusion tensor imaging (DTI), in patients experiencing a first-episode of schizophrenia at the onset of treatment and then following 12 weeks of standarized treatment. It is hypothesized that patients will demonstrate white matter abnormalities in the frontal and temporal lobes at the baseline and that increases in white matter integrity will occur in these regions following antipsychotic treatment. This data will be used to demonstrate feasibility of collection of longitudinal DTI data for a future grant submission to the NIMH.